Renal cell carcinoma and antiangiogenic therapies;Antiangiogenèse et cancer du rein

Presse Medicale

Volumn 37, Issue 4 PART 2, 2008, Pages 628-633

  Pouessel, Damien ^a   Culine, Stéphane ^a   Verhoest, Gregory ^b   Patard, Jean Jacques ^b  

^a Lab d'Oncopharmacologie pharmacie Ctr Regl Lutte contre le Cancer V   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; INTERLEUKIN 2; PLACEBO; PROTEIN KINASE INHIBITOR; RAPAMYCIN; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; ASTHENIA; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DYSPNEA; EPISTAXIS; EVENING DOSAGE; HAND FOOT SYNDROME; HEMATURIA; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LYMPHADENOPATHY; METASTASIS; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEUTROPENIA; PROTEINURIA; RECOMMENDED DRUG DOSE; SHORT SURVEY; STOMATITIS; THROMBOCYTOPENIA;

EID: 40949162343     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2007.07.007     Document Type: Short Survey

References (11)

1. Pouessel D., and Culine S. Targeted therapies in metastatic renal cell carcinoma : the light at the end of the tunnel. Exp Rev Anticancer Ther 6 (2006) 1761-1767
2. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
3. Wilhelm S.M., Carter C., Tang L.Y., Wilkie D., McNabola A., Rong H., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the Raf/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
4. Ratain M.J., Eisen T., Stadler W.M., Flaherty K.T., Kaye S.B., Rosner G.L., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
5. Escudier B., Eisen T., Stadler W.M., Szczylik C., Oudard S., Siebels M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356 (2007) 125-134
6. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
7. Motzer R.J., Rini B.I., Bukowski R.M., Curti B.D., George D.J., Hudes G.R., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
8. Motzer R.J., Hutson T.E., Tomczak P., Michaelson M.D., Bukowski R.M., Rixe O., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
9. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
10. Hudes G., Carducci M., Tomczak P., Dutcher J., Figlin R., Kapoor A., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma. Proc Am Soc Clin Oncol 24 (2006) 930s (Abstract LBA4)
11. Yang J.C., Haworth L., Sherry R.M., Hwu P., Schwartzentruber D.J., Topalian S.L., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434